UBS Group
PRME icon

UBS Group’s Prime Medicine PRME Stock Holding History

UBS Group’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Sell
2,794,689
-93,729
-3% -$311K ﹤0.01% 3407
2026
Q1 		$10.1M Buy
2,888,418
+447,835
+18% +$1.7M ﹤0.01% 3346
2025
Q4 		$8.47M Buy
2,440,583
+2,135,810
+701% +$9.5M ﹤0.01% 3466
2025
Q3 		$1.69M Buy
304,773
+109,446
+56% +$445K ﹤0.01% 5121
2025
Q2 		$482K Buy
195,327
+77,647
+66% +$120K ﹤0.01% 6036
2025
Q1 		$234K Sell
117,680
-100,506
-46% -$256K ﹤0.01% 6435
2024
Q4 		$637K Buy
218,186
+183,165
+523% +$643K ﹤0.01% 5670
2024
Q3 		$136K Buy
35,021
+12,482
+55% +$57.8K ﹤0.01% 6144
2024
Q2 		$116K Sell
22,539
-19,984
-47% -$121K ﹤0.01% 6078
2024
Q1 		$298K Buy
42,523
+11,111
+35% +$84.3K ﹤0.01% 5577
2023
Q4 		$278K Sell
31,412
-12,360
-28% -$95.2K ﹤0.01% 5552
2023
Q3 		$418K Sell
43,772
-55,267
-56% -$718K ﹤0.01% 4797
2023
Q2 		$1.45M Buy
99,039
+94,104
+1,907% +$1.31M ﹤0.01% 3859
2023
Q1 		$60.7K Buy
4,935
+3,726
+308% +$60.7K ﹤0.01% 6301
2022
Q4 		$22.5K Buy
+1,209
New +$21.8K ﹤0.01% 7537

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

UBS Group's PRME Position: Q2 2026 in Review

UBS Group reduced its Prime Medicine (PRME) stake by 3.2% in Q2 2026, selling an estimated $311K and leaving 2,794,689 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3407.

UBS Group first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • UBS Group held 2,794,689 shares of Prime Medicine worth $10.3M as of Q2 2026.
  • UBS Group sold 93,729 Prime Medicine shares in Q2 2026, an estimated $311K.
  • Prime Medicine made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3407 holding.
  • UBS Group first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.